Honeywell Receives Pharmaceutical Automation Award From Frost & Sullivan

  • May 20, 2004
  • Honeywell Process Solutions
  • News
"Customer Value Leadership" Award Recognizes Excellence in Serving Pharmaceutical CustomersPHOENIX, May 20, 2004 - Honeywell (NYSE: HON) has received Frost and Sullivan's prestigious Pharmaceutical Automation Customer Value Leadership (CVL) of the Year Award. Frost & Sullivan, a global leader in growth consulting, presents the award each year to the company that has best demonstrated the ability to expand its customer base, while leveraging existing strengths with more innovative value-creation and enhancement strategies than competing vendors. This award recognizes Honeywell's successful sales entry, customer acquisition and service strategies and the degree to which those strategies have met customer needs."Honeywell has shown exceptional understanding of the business needs of pharmaceutical customers," says Frost & Sullivan team leader Sath Rao. "Its ability to take responsibility for consulting and validation services, automation, manufacturing execution systems deployment, and consistent, on-time deliveries, has helped the company generate repeat orders from its installed base.""Many pharmaceutical customers have selected Honeywell as their one-stop-shop for systems and services," said Rao. "By taking this umbrella approach, customers enjoy the convenience of working with one vendor and greater confidence that they are in compliance with current and emerging regulatory requirements, such as FDA 21 CFR Part 11.""The Frost and Sullivan award win illustrates Honeywell's understanding of our pharmaceutical customers' business needs," said Jack Bolick, President, Honeywell Process Solutions. "Relationship-building efforts have significantly contributed to Honeywell's generating repeat orders from our installed customer base as well as new orders in the pharmaceutical industry."Using a variety of Honeywell products and services, pharmaceutical customers can achieve compliance to current and emerging regulatory requirements, such as FDA 21 CFR Part 11, with the added advantage of employing just one vendor. Having a single interface is particularly beneficial because pharmaceutical applications require stringent record keeping and reporting. For example, customers must monitor indoor air quality and indoor air cycles, while maintaining corresponding records tagged to batch lot numbers. One way that Honeywell tackles these strict demands is through pharmaceutical facility management solutions, which help customers control costs. The Honeywell Enterprise Building Integrator (EBI) facility management system is an example of a core platform that integrates information from different enterprise sub-systems, including process automation platforms, environmental control systems and MES. EBI allows customers to use one system to meet their challenging needs and eliminates concern about integration loopholes and cost overages.Customers have also reported dramatic returns on investments after implementing Honeywell POMS® MES solutions. By integrating best practices with quality and regulatory compliance, Honeywell pharmaceutical solutions have enabled customers to minimize risk, increase throughput, lower production costs, and reduce time-to-market.Honeywell POMS MES has proven especially effective in resolving customers' problems with batch records and product recipes. A market leader in the pharmaceutical segment, POMS MES surpasses other electronic batch record (EBR) solutions in the industry. Flexible and intuitive, the technology solution provides links to enterprise resource planning software and advanced factory scheduling (AFS) applications, which offer specialized approaches to optimize production. The Honeywell Document RX asset management solution complements POMS MES by helping customer's track maintenance procedures and standards and monitor work order management.To qualify for a Frost and Sullivan CVL award, candidates must meet predetermined criteria set by industry analysts. Through primary and secondary research methods, analysts track companies' market positions and market growth, and compare their customer install-bases and revenues year-to-year to monitor customer response and market expansion. When a company continues to capitalize on market opportunities with innovative solutions, while driving customer value, it becomes a candidate for the CVL Award.Honeywell International is a $23 billion diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; specialty chemicals; fibers; and electronic and advanced materials. Based in Morris Township, N.J., Honeywell's shares are traded on the New York, London, Chicago and Pacific Stock Exchanges. It is one of the 30 stocks that make up the Dow Jones Industrial Average and is also a component of the Standard & Poor's 500 Index. For additional information, please visit Process Solutions is part of Honeywell's Automation and Control Solutions group, a global leader in providing product and service solutions that improve efficiency and profitability, support regulatory compliance, and maintain safe, comfortable environments in homes, buildings and industry. For more information about Process Solutions, access This release contains forward-looking statements as defined in Section 21E of the Securities Exchange Act of 1934, including statements about future business operations, financial performance and market conditions. Such forward-looking statements involve risks and uncertainties inherent in business forecasts as further described in our filings under the Securities Exchange Act.

Did you enjoy this great article?

Check out our free e-newsletters to read more great articles..